Australia is lagging behind the rest of the world when it comes to the use of botulinim toxin for post-stroke spasticity, new figures suggest. The Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee (PBAC) has noted that the use of botulinum toxin is low in the context of post-stroke spasticity. It found 742 ...
PBS funding rules blamed for underuse of Botox in post-stroke spasticity
By Mardi Chapman
19 Jul 2018